Multidrug resistance is a global healthcare problem. Gram-negative organisms, particularly Enterobacteriaceae strains are responsible for almost 60% of nosocomial infections. Colistin acts as the last treatment resort in complicated, critical, and MDR cases; also become resistant in the last few years in an escalating manner. Its resistance has been reported almost all over the world. Since there is no alternative antibiotic of colistin-resistant isolates is available. The last year of 2020 was completely engaged with the Covid-19 pandemic for global healthcare systems. This issue is still persisting with no solution. Strict infection control policies and a noval antibiotic with lesser side effects are great in demand to resolve this issue.

We gathered 28 studies from 2010 that reported colistin resistance among Enterobacteriaceae throughout the world. Colistin resistance still reported and escalated globally with no available solution. Asia was the leading region with 50% of selected studies followed by Europe and Klebsiella pneumonia and Klebsiella species were the leading organisms of colistin resistance among Enterobacteriaceae. 

This mini-review was designed to highlight the global importance of colistin-resistant isolates among Enterobacteriaceae, which still an unanswered question.